A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity

NCT06916065 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: Eloralintide and Tirzepatide
DRUG: Eloralintide

Sponsor

Eli Lilly and Company